Sol-gel Technologies Ltd. · NASDAQ:SLGL
Sol-gel Technologies — Investor Presentation (June 2022)
22 slides from Sol-gel Technologies's investor presentation, Jun 8, 2022
Slide 1: Sol-Gel: Advanced Topical Therapy
$ Sol- Gel ay nced Topical Therapy
Slide 2: Forward-looking statements
This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limit
Slide 3: Pioneering Topical Dermatological Drugs: Two FDA Approvals Within One Year
PIONEERING TOPICAL DERMATOLOGICAL DRUGS Two FDA Approvals Within One Year Not a real patient Not a real patient
Slide 4: TWYNEO for Acne Was Launched
Say hello to thisnever-before-seen combo TWYNEO® FOR ACNE WAS LAUNCHED First and only FDA Approved Fixed‑Dose Combination of Tretinoin and Benzoyl Peroxide
Slide 5: TWYNEO Remarkably Growing Sales
TWYNEO® FOR ACNE WAS LAUNCHED Remarkably Growing Sales * IQVIA
Slide 6: TWYNEO Offers Comprehensive Treatment for Acne Patients
TWYNEO® OFFERS COMPREHENSIVE TREATMENT FOR ACNE PATIENTS Potential to Become 1st Line Treatment Acne vulgaris is a multifactorial disease. Even though benzoyl peroxide and tretinoin are widely prescribed separately and have a complementary mechanism of action, so far, they could not be applied conco
Slide 7: Treating Severe Acne Patient with TWYNEO
* Individual results vary BASELINE “Severe”; 29 inflamed lesions 31 non-inflamed lesions; 1 nodule WEEK 12 “Moderate”; 9 inflamed lesions 5 non-inflamed lesions; No nodules TREATING SEVERE ACNE PATIENT WITH TWYNEO® Subject 507-003 || 18 Years Old | Female | White | Not Hispanic or Latino*
Slide 8: EPSOLAY for Inflammatory Lesions of Rosacea Was Approved
EPSOLAY® FOR INFLAMMATORY LESIONS OF ROSACEA WAS APPROVED First and only Benzoyl Peroxide in Rosacea Rosacea care with the brilliant touch of technology
Slide 9: EPSOLAY Offers Effective Topical Treatment for Rosacea Patients
EPSOLAY® OFFERS EFFECTIVE TOPICAL TREATMENT FOR ROSACEA PATIENTS Potential to Change Treatment Landscape Inflammatory lesions of rosacea resemble acne vulgaris, except that comedones (whiteheads and blackheads) are absent and only inflammatory lesions exist EPSOLAY contains encapsulated benzoyl pero
Slide 10: Treating Severe Rosacea Patient with EPSOLAY
BASELINE “Severe”; 31 inflamed lesions WEEK 2 “Clear”; No inflamed lesions “Clear”; No inflamed lesions WEEK 12 “Almost Clear”; 1 inflamed lesion WEEK 8 “Clear”; No inflamed lesions TREATING SEVERE ROSACEA PATIENT WITH EPSOLAY® Subject 116-009 || 41 Years Old | Female | White | Not Hispanic or Latin
Slide 11: Partnering with Market Leader Galderma
PARTNERING WITH MARKET LEADER GALDERMA Galderma has Heritage of Successful Drugs in Acne and Rosacea
Slide 12: Reaching Favorable Agreement with Galderma
REACHING FAVORABLE AGREEMENT WITH GALDERMA Option to Regain Commercialization Rights at No Cost 5 Years following 1st Sale $11 million in upfront and product approval payments Mid- to high-teen percentage of royalties on net sales Up to additional $9 million in sales milestone payments Option to reg
Slide 13: Implementing Innovation: Enabling Microencapsulation Technology
IMPLEMENTING INNOVATION Enabling Microencapsulation Technology Proprietary silica-based microencapsulation technology allows development of drugs that have the potential to be more effective and tolerable than existing drugs Core/shell structure designed to boost tolerability High encapsulation effi
Slide 14: TWYNEO indication and safety information
Indication: TWYNEO® (tretinoin and benzoyl peroxide) Cream, 0.1%/3% is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with TWYNEO Cream were pain (s
Slide 15: Pursuing Leadership in Dermatology: Innovative Pipeline
SGT-510 Topical Roflumilast + “Agent A”Psoriasis & Other Dermatologic Indications PURSUING LEADERSHIP IN DERMATOLOGY Innovative Pipeline of Topical Skin Medications SGT-210 Topical ErlotinibKeratoderma & Other Dermatologic Indications SGT-310 Tapinarof CreamPsoriasis & Other Dermatologic Indications
Slide 16: Developing First Erlotinib Topical Drug SGT-210
Initiate clinical development with a higher concentration of erlotinib in H1 23 DEVELOPING FIRST ERLOTINIB TOPICAL DRUG SGT-210 for Keratoderma and other Skin Conditions NEXT STEPS SGT-210 20 patent applications for erlotinib in various skin conditions (as of May 12, 2021)Potential IP protection unt
Slide 17: Developing Novel Tapinarof Cream SGT-310
Initiate clinical development in H1 23 DEVELOPING NOVEL TAPINAROF CREAM SGT-310 for Psoriasis and other Skin Conditions NEXT STEPS SGT-310 42 patent applications for tapinarof in various skin conditions (as of May 12, 2021)Potential IP protection until 2042 Intended to be an alternative to an FDA ap
Slide 18: Developing Novel Roflumilast Combination Topical Drug SGT-510
DEVELOPING NOVEL ROFLUMILAST COMBINATION TOPICAL DRUG SGT-510 (Roflumilast + “Agent A”) for Psoriasis and other Skin Conditions NEXT STEPS SGT-510 Initiate clinical development in H2 22 A patent application was filed Potential IP protection until 2039 Designed to be potentially more effective than r
Slide 19: Focusing on Pipeline While Securing Non-Dilutive Funding
FOCUSING ON INNOVATIVE PIPELINE WHILE SECURING NON-DILUTIVE FUNDING Sale of Generic Assets to Padagis Sale of Generic Assets to Padagis in return for $21 million in quarterly installments over 24 months Proceed with 50/50 gross profit-sharing collaboration on 2 programs encompassing 4 high-value gen
Slide 20: Securing a Strong Balance Sheet: Financial Profile
Financials March 31, 2022 Cash and Investments $36.3 million Shares Outstanding 23,119,068 ordinary shares Expected Partnership Payments Quarterly payments by Padagis; Royalties from Galderma Cash Runway Based on expected payments from Galderma and Padagis, we anticipate that our cash resources will
Slide 21: Building Our Future: Investor Highlights
BUILDING OUR FUTURE Investor Highlights Completed development of EPSOLAY and TWYNEO and gained FDA approvals Maximized likelihood of market success for EPSOLAY and TWYNEO through commercialization agreements with US market leader, while retaining the option to regain commercialization rights 5 years
Slide 22: Sol-Gel: Advanced Topical Therapy
$ Sol- Gel ay nced Topical Therapy
Sol-Gel Technologies — Investor Presentation (June 2022) on 6ix